101 related articles for article (PubMed ID: 16445592)
1. Effects of premedication medicines on the formation of the CYP3A4-dependent metabolite of ropivacaine, 2', 6'-Pipecoloxylidide, on human liver microsomes in vitro.
Tanaka E; Nakamura T; Inomata S; Honda K
Basic Clin Pharmacol Toxicol; 2006 Feb; 98(2):181-3. PubMed ID: 16445592
[TBL] [Abstract][Full Text] [Related]
2. A study of the in vitro interaction between lidocaine and premedications using human liver microsomes.
Nagashima A; Tanaka E; Inomata S; Honda K; Misawa S
J Clin Pharm Ther; 2005 Apr; 30(2):185-8. PubMed ID: 15811173
[TBL] [Abstract][Full Text] [Related]
3. Premedication medicines do not cause drug metabolic interaction with propofol using human liver microsomes in vitro.
Tanaka E; Takano Y; Inomata S; Toyooka H; Honda K
Eur J Clin Pharmacol; 2004 Oct; 60(8):565-8. PubMed ID: 15351923
[TBL] [Abstract][Full Text] [Related]
4. A study of the in vitro clinical interaction between lidocaine and premedications using rat liver microsomes.
Nagashima A; Tanak E; Inomata S; Misawa S
Hum Exp Toxicol; 2002 Aug; 21(8):453-6. PubMed ID: 12412639
[TBL] [Abstract][Full Text] [Related]
5. Ropivacaine, a new amide-type local anesthetic agent, is metabolized by cytochromes P450 1A and 3A in human liver microsomes.
Ekström G; Gunnarsson UB
Drug Metab Dispos; 1996 Sep; 24(9):955-61. PubMed ID: 8886604
[TBL] [Abstract][Full Text] [Related]
6. Effect of propofol on ropivacaine metabolism in human liver microsomes.
Osaka Y; Inomata S; Tanaka E; Nakamura T; Honda K; Miyabe M; Toyooka H; Tanaka M
J Anesth; 2006; 20(1):60-3. PubMed ID: 16421682
[TBL] [Abstract][Full Text] [Related]
7. Regional transport and metabolism of ropivacaine and its CYP3A4 metabolite PPX in human intestine.
Berggren S; Lennernäs P; Ekelund M; Weström B; Hoogstraate J; Lennernäs H
J Pharm Pharmacol; 2003 Jul; 55(7):963-72. PubMed ID: 12906753
[TBL] [Abstract][Full Text] [Related]
8. Metabolism of a new local anesthetic, ropivacaine, by human hepatic cytochrome P450.
Oda Y; Furuichi K; Tanaka K; Hiroi T; Imaoka S; Asada A; Fujimori M; Funae Y
Anesthesiology; 1995 Jan; 82(1):214-20. PubMed ID: 7832304
[TBL] [Abstract][Full Text] [Related]
9. Effect of ciprofloxacin on the pharmacokinetics of ropivacaine.
Jokinen MJ; Olkkola KT; Ahonen J; Neuvonen PJ
Eur J Clin Pharmacol; 2003 Feb; 58(10):653-7. PubMed ID: 12610740
[TBL] [Abstract][Full Text] [Related]
10. Oxidative metabolism of bupivacaine into pipecolylxylidine in humans is mainly catalyzed by CYP3A.
Gantenbein M; Attolini L; Bruguerolle B; Villard PH; Puyoou F; Durand A; Lacarelle B; Hardwigsen J; Le-Treut YP
Drug Metab Dispos; 2000 Apr; 28(4):383-5. PubMed ID: 10725304
[TBL] [Abstract][Full Text] [Related]
11. Metabolism of ropivacaine in humans is mediated by CYP1A2 and to a minor extent by CYP3A4: an interaction study with fluvoxamine and ketoconazole as in vivo inhibitors.
Arlander E; Ekström G; Alm C; Carrillo JA; Bielenstein M; Böttiger Y; Bertilsson L; Gustafsson LL
Clin Pharmacol Ther; 1998 Nov; 64(5):484-91. PubMed ID: 9834040
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetic analysis of ropivacaine and its metabolite 2',6'-pipecoloxylidide from pooled data in neonates, infants, and children.
Aarons L; Sadler B; Pitsiu M; Sjövall J; Henriksson J; Molnár V
Br J Anaesth; 2011 Sep; 107(3):409-24. PubMed ID: 21693469
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of ropivacaine in patients with chronic renal failure.
Pere PJ; Ekstrand A; Salonen M; Honkanen E; Sjövall J; Henriksson J; Rosenberg PH
Br J Anaesth; 2011 Apr; 106(4):512-21. PubMed ID: 21307007
[TBL] [Abstract][Full Text] [Related]
14. Inhibition and kinetics of cytochrome P4503A activity in microsomes from rat, human, and cdna-expressed human cytochrome P450.
Ghosal A; Satoh H; Thomas PE; Bush E; Moore D
Drug Metab Dispos; 1996 Sep; 24(9):940-7. PubMed ID: 8886602
[TBL] [Abstract][Full Text] [Related]
15. Effects of clonidine pre-treatment on bupivacaine and ropivacaine cardiotoxicity in rats.
Gulec S; Aydin Y; Uzuner K; Yelken B; Senturk Y
Eur J Anaesthesiol; 2004 Mar; 21(3):205-9. PubMed ID: 15055893
[TBL] [Abstract][Full Text] [Related]
16. Metabolism and excretion of ropivacaine in humans.
Halldin MM; Bredberg E; Angelin B; Arvidsson T; Askemark Y; Elofsson S; Widman M
Drug Metab Dispos; 1996 Sep; 24(9):962-8. PubMed ID: 8886605
[TBL] [Abstract][Full Text] [Related]
17. Human cytochrome P450 3A (CYP3A) mediated midazolam metabolism: the effect of assay conditions and regioselective stimulation by alpha-naphthoflavone, terfenadine and testosterone.
Mäenpää J; Hall SD; Ring BJ; Strom SC; Wrighton SA
Pharmacogenetics; 1998 Apr; 8(2):137-55. PubMed ID: 10022752
[TBL] [Abstract][Full Text] [Related]
18. The effect of a long term epidural infusion of ropivacaine on CYP2D6 activity.
Wink J; Veering BT; Kruit M; Burm AG; Huledal GA; Ekström GY; Stienstra R; van Kleef JW
Anesth Analg; 2008 Jan; 106(1):143-6, table of contents. PubMed ID: 18165569
[TBL] [Abstract][Full Text] [Related]
19. High-performance liquid chromatographic determination of ropivacaine, 3-hydroxy-ropivacaine, 4-hydroxy-ropivacaine and 2',6'-pipecoloxylidide in plasma.
Reif S; Le Corre P; Dollo G; Chevanne F; Le Verge R
J Chromatogr B Biomed Sci Appl; 1998 Nov; 719(1-2):239-44. PubMed ID: 9869387
[TBL] [Abstract][Full Text] [Related]
20. Effect of rifampin and tobacco smoking on the pharmacokinetics of ropivacaine.
Jokinen MJ; Olkkola KT; Ahonen J; Neuvonen PJ
Clin Pharmacol Ther; 2001 Oct; 70(4):344-50. PubMed ID: 11673750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
